Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
4.930
+0.160 (3.35%)
Nov 21, 2024, 12:54 PM EST - Market open
Tenax Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
16.81M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 64.15M |
Retractable Technologies | 38.27M |
Marinus Pharmaceuticals | 31.47M |
Lifeward | 25.00M |
Nephros | 13.55M |
Cara Therapeutics | 8.69M |
Kazia Therapeutics | 1.66M |
Innovative Eyewear | 1.56M |
TENX News
- 6 days ago - Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) - Seeking Alpha
- 8 days ago - Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 20 days ago - Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement - GlobeNewsWire
- 6 months ago - Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 8 months ago - Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” - GlobeNewsWire
- 8 months ago - Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - GlobeNewsWire